Sources agree on the $56 million Series A, announcement date, lead investors, and participating investors. Source 4 says the round was "co-led" while the company release says "led by"; the company release is preferred.
[ BUILT WITH ]·[ SEARCH ]found by corroboration·[ SCRAPE ]5 pages read: finance.yahoo.com, pulse2.com, typewritertx.com·[ JSON ]round extracted with a schema, grounded to one sentence·[ VERIFY ]confirmedread back across 5 sources by gpt-5.6-luna·[ BRANDING ]logo and colour from the homepage·[ ALEXANDRIA ]firmographics from FullEnrich via Alexandria
Sources agree on the $56 million Series A, announcement date, lead investors, and participating investors. Source 4 says the round was "co-led" while the company release says "led by"; the company release is preferred.
[ BUILT WITH ]·[ SEARCH ]found by corroboration
Profile
[ ENRICHED ]
Does
Typewriter Therapeutics sells an all-RNA platform for non-viral gene therapy aimed at treating cancer and severe genetic diseases.
Headcount
34
Type
Privately Held
Industry
Biotechnology Research
Via Alexandria from FullEnrich: headcount, type, industry
